Definition of the Term “Biological Product” Final Regulatory Impact Analysis
The Food and Drug Administration is issuing a final rule to amend its regulation that defines "biological product" to incorporate changes made by the Biologics Price Competition and Innovation Act of 2009 (BPCI Act) and the Further Consolidated Appropriations Act, 2020 (FCA Act), and to provide its interpretation of the statutory term "protein." Under this final rule, the term protein means any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size. This final rule is intended to clarify the statutory framework under which such products are regulated.
Regulatory Impact Analysis
Definition of the Term “Biological Product” (PDF – 158KB)
Federal Register: 85 FR 10057, February 21, 2020
Docket: FDA-2018-N-2732